Zobrazeno 1 - 10
of 14
pro vyhledávání: '"A Gene Trimble"'
Publikováno v:
Clinical Pharmacology & Therapeutics; Mar1988, Vol. 43 Issue 3, p290-301, 12p
Publikováno v:
Clinical Pharmacology & Therapeutics; Aug1980, Vol. 28 Issue 2, p270-277, 8p
Publikováno v:
Clinical Pharmacology and Therapeutics. 32:407-417
The average number of self-originated new chemical entities (NCEs) first tested in man by 39 United States-owned pharmaceutical firms in the 3-year period from 1977 to 1979 was 26 a year, approximately half the number investigated annually in the pre
Autor:
Richard N. Spivey, A Gene Trimble
Publikováno v:
Drug Information Journal. 20:27-35
We undertook a comprehensive retrospective analysis of already-approved drugs to assess the likely impact of the Drug Price Competition and Patent Term Restoration Act on market exclusivity of future new drugs. We analyzed data for new drugs approved
Publikováno v:
Clinical Pharmacology and Therapeutics. 41:368-370
For 55 individual drugs, the time required for approval of the original new drug application (NDA) was compared with the time required for approval of supplemental NDAs. The mean time required for the original NDAs was 22.2 ± 18.1 months; the mean f
Publikováno v:
Clinical Pharmacology & Therapeutics; August 1980, Vol. 28 Issue: 2 p270-277, 8p
Publikováno v:
Clinical pharmacology and therapeutics. 37(4)
Autor:
A Gene Trimble, Henry T Davis, Christopher Cox, Lorraine Sheck, Ronald Hansen, William M Wardell
Publikováno v:
Clinical pharmacology and therapeutics. 36(5)
Drug development in the United States has been characterized by: (1) high attrition and correspondingly low success rates of drug candidates passing through the development sys(2) a steady decline in new chemical entities (NCEs) entering clinical r e
Publikováno v:
Regulatory toxicology and pharmacology : RTP. 4(2)
This study of the development and regulation of self-originated new chemical entities (NCEs) in Switzerland between 1960 and 1980 is based on confidential data obtained through a survey of the three largest Swiss companies. Analyses of these data all
Publikováno v:
Clinical pharmacology and therapeutics. 43(3)
This study is the fifth in a series that documents changes in the status of drug development in the United States based on a survey of the pharmaceutical industry. For example, the study shows that, although there has been a recent increase in the nu